WallStSmart

Frontdoor Inc (FTDR)vsMEDIFAST INC (MED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Frontdoor Inc generates 577% more annual revenue ($2.15B vs $316.93M). FTDR leads profitability with a 12.8% profit margin vs -8.1%. MED appears more attractively valued with a PEG of 0.97. FTDR earns a higher WallStSmart Score of 59/100 (C).

FTDR

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 8.5Value: 4.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.33

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.0Quality: 8.5
Piotroski: 2/9Altman Z: 5.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FTDRSignificantly Overvalued (-32.5%)

Margin of Safety

-32.5%

Fair Value

$42.49

Current Price

$81.01

$38.52 premium

UndervaluedFair: $42.49Overvalued

Intrinsic value data unavailable for MED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FTDR2 strengths · Avg: 9.0/10
Return on EquityProfitability
113.0%10/10

Every $100 of equity generates 113 in profit

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

MED4 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.0910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.978/10

Growing faster than its price suggests

Areas to Watch

FTDR4 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

Price/BookValuation
19.8x4/10

Trading at 19.8x book value

Revenue GrowthGrowth
4.5%4/10

4.5% revenue growth

Debt/EquityHealth
4.141/10

Elevated debt levels

MED4 concerns · Avg: 2.5/10
Market CapQuality
$141.66M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-10.1%2/10

ROE of -10.1% — below average capital efficiency

Revenue GrowthGrowth
-27.6%2/10

Revenue declined 27.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : FTDR

The strongest argument for FTDR centers on Return on Equity, Operating Margin.

Bull Case : MED

The strongest argument for MED centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : FTDR

The primary concerns for FTDR are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

FTDR profiles as a value stock while MED is a turnaround play — different risk/reward profiles.

FTDR carries more volatility with a beta of 1.51 — expect wider price swings.

FTDR is growing revenue faster at 4.5% — sustainability is the question.

FTDR generates stronger free cash flow (120M), providing more financial flexibility.

Bottom Line

FTDR scores higher overall (59/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Frontdoor Inc

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

front door, inc. The company is headquartered in Memphis, Tennessee.

Visit Website →

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Want to dig deeper into these stocks?